NVAX rises impending an earnings report LONG
Today NVAX is selling for a tiny fraction of its all-time high as shown in a previous idea. Earnings
is coming this upcoming week. This week NVAX news release showed it had settled a years long
litigation over a failed COVID. In the face of earnings around the corner, was this news release
a coincidence or instead a case of excellent executive and legal timing? I will skip the
conspiracy discussion.
On the chart, NVAX's bullish momentum is clear on its face. A price rise of 22% from a stock
that has been stuck in deeply undervalued territory for a significant time period is remarkable.
I have bought far out of the money call options into 2025 and 2026 some only this past month.
Those from this month are now up over 250% with 11 and 23 months to go to expiration.
I see NVAX as a risky penny medical stock with a high reward potential relative to the
risk. It is a potential buy-out candidate and bankruptcy is less likely. The rich uncle is
MRNA but the richer uncle in PFE might gain some interest. The wisest of capitalists buy out
the competition when there is an opportunity and do not worry about the government crying
monopoly when life-saving and life-extending medical products are involved. Time will tell.
I expect insane profits.
is coming this upcoming week. This week NVAX news release showed it had settled a years long
litigation over a failed COVID. In the face of earnings around the corner, was this news release
a coincidence or instead a case of excellent executive and legal timing? I will skip the
conspiracy discussion.
On the chart, NVAX's bullish momentum is clear on its face. A price rise of 22% from a stock
that has been stuck in deeply undervalued territory for a significant time period is remarkable.
I have bought far out of the money call options into 2025 and 2026 some only this past month.
Those from this month are now up over 250% with 11 and 23 months to go to expiration.
I see NVAX as a risky penny medical stock with a high reward potential relative to the
risk. It is a potential buy-out candidate and bankruptcy is less likely. The rich uncle is
MRNA but the richer uncle in PFE might gain some interest. The wisest of capitalists buy out
the competition when there is an opportunity and do not worry about the government crying
monopoly when life-saving and life-extending medical products are involved. Time will tell.
I expect insane profits.
Zlecenie aktywne:
Another idea if you like deeply undervalued biotech penny stocks with upcoming earnings
Komentarz:
Zlecenie aktywne:
Price breaking out of local volume profile and VWAP bands about 6:35 EST in the pre-market and will likely continue after the open.
Zlecenie aktywne:
NVAX BULLISH MOMENTUM CONTINUES 35% IN THE PAST SIX TRADING DAYS-
LINK TO NEWS CTALYST finance.yahoo.com/ne...oblem-103000554.html
LINK TO NEWS CTALYST finance.yahoo.com/ne...oblem-103000554.html
Komentarz:
NVAX with sustained bullish momentum